Rheumatoid arthritis (RA) is an autoimmune disease. It develops when the immune system, which normally fights infections, mistakenly attacks healthy tissue in the joints. About 18 million people worldwide live with RA, and women are two to three times more likely to develop it than men.
Why RA Is Classified as Autoimmune
The immune system produces specialized cells and antibodies designed to identify and destroy foreign invaders like bacteria and viruses. In RA, these same defenses turn inward. Immune cells target the synovium, a thin membrane that lines and lubricates your joints, treating it as if it were a threat. This misdirected attack is the defining feature of an autoimmune disorder: the body’s defense system damages its own tissue.
Specifically, immune cells including T cells, B cells, and macrophages flood into the joint lining, which is normally just a few cells thick. Macrophages act as the primary drivers of damage, pumping out inflammatory signaling molecules that recruit even more immune cells and ramp up the assault. These signals simultaneously break down existing cartilage and prevent new cartilage from forming. Over time, that unchecked inflammation erodes cartilage, weakens bone, and can permanently deform the joint.
What Triggers the Immune System to Attack
No single cause explains why the immune system turns on the joints, but a combination of genetics and environmental exposures sets the stage. Genetic factors account for a significant portion of RA risk, with the strongest link tied to specific variations in genes that help the immune system distinguish “self” from “foreign.” If you carry certain versions of these genes, your immune cells may be more prone to misidentifying your own joint tissue as a threat.
Genetics alone don’t cause RA, though. Environmental triggers appear to tip a genetically susceptible person into active disease. Smoking is the most well-established of these triggers, particularly for people who test positive for certain RA-related antibodies. Oral bacteria, especially those involved in gum disease, have also drawn attention from researchers. One bacterium commonly found in periodontitis can modify proteins in a way that closely resembles the protein changes seen in RA joints, potentially confusing the immune system. Gut bacteria have come under scrutiny too, with specific intestinal microbes linked to immune responses that overlap with RA.
How RA Feels Different From Osteoarthritis
Many people searching about RA are trying to figure out whether their joint pain is “regular” arthritis or something more. The distinction matters because RA and osteoarthritis have fundamentally different causes. Osteoarthritis is a wear-and-tear problem where cartilage gradually breaks down. RA is the immune system actively destroying joint tissue.
The most telling difference is morning stiffness. In osteoarthritis, stiffness after sleeping or sitting typically loosens up within a few minutes of moving around. In RA, morning stiffness lasts an hour or longer, and prolonged stiffness upon waking is sometimes the very first symptom people notice. RA also tends to affect joints symmetrically, hitting both wrists or both sets of knuckles, and it favors smaller joints in the hands and feet early on. Osteoarthritis more commonly strikes weight-bearing joints like knees and hips.
How RA Is Diagnosed
Doctors use a points-based scoring system developed jointly by the American College of Rheumatology and the European League Against Rheumatism. The system evaluates four domains: how many and which joints are involved, whether specific antibodies show up in blood work, whether markers of inflammation are elevated, and how long symptoms have lasted. A score of 6 out of 10 or higher, combined with confirmed joint swelling that can’t be better explained by another condition, leads to an RA classification.
Two blood markers carry the most diagnostic weight. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are both signs that the immune system is producing antibodies against the body’s own proteins. Testing strongly positive for either one contributes up to 3 points toward the diagnostic threshold. Elevated inflammation markers in the blood add another point, and symptoms lasting six weeks or more add one more. You don’t need to test positive for every marker to be diagnosed, since the scoring system accounts for different combinations.
Effects Beyond the Joints
Because RA is a systemic autoimmune disease, the same inflammatory process that attacks joints can affect other parts of the body. The lungs, heart, eyes, mouth, and skin are all potential targets. Without treatment, RA increases the risk of heart disease and a form of lung scarring called interstitial lung disease. Chronic dry eyes and dry mouth are also common complications. These extra-articular effects underscore why RA is more than “just arthritis.” The inflammation circulating through your body can quietly damage organs even when joint symptoms feel manageable.
How Treatment Works
Since RA is driven by the immune system, treatment focuses on calming or redirecting that immune response rather than simply managing pain. The standard approach follows a “treat-to-target” strategy where the explicit goal is remission, not just symptom relief.
Treatment typically starts with a conventional disease-modifying drug, often paired with a short course of a corticosteroid to bring inflammation down quickly. If that first-line approach doesn’t achieve low disease activity within a few months, doctors add a biologic therapy or a newer targeted oral medication. Biologics work by blocking specific inflammatory signals. Some neutralize the key signaling molecules that macrophages release to drive joint destruction. Others reduce the activity of B cells or T cells directly. Targeted oral therapies interrupt the signaling pathways inside immune cells that keep the inflammatory cycle going.
Modern treatment has made remission a realistic outcome for many people. In a large study of nearly 22,000 RA patients in England and Wales tracked between 2018 and 2024, about 35% achieved remission within three months of starting treatment. Rates varied by region, ranging from roughly 28% to 40%, but the overall picture is considerably more hopeful than it was a generation ago when RA almost inevitably meant progressive joint destruction. Early, aggressive treatment gives the best chance of halting the disease before permanent damage occurs.